Site menu
Menu
ASX dividend shares are some of the best in the world, given their yield and the fact that many Australian companies offer their dividends with franking credits.
Below, you’ll find share research and analysis on some of Australia’s best (and worst) ASX dividend shares, stock ideas and the latest news from Rask Media — delivered daily.
Is JB Hi-Fi Limited (ASX: JBH) the ASX’s best business model? Drew thinks so. Or is Pinnacle Investment Management Ltd (ASX: PNI) a much better business?
The Commonwealth Bank of Australia (ASX: CBA) share price jumped after reporting results. But was it really a good result for CBA shareholders? Stock Doctor’s Daniel Ortisi takes a deep look.
The Nick Scali Limited (ASX:NCK) share price has gone up after revealing a strong FY23 report and generous dividend.
The team at Stock Doctor initiated coverage of ARF as a Star Income Stock in 2017 at a share price of $2.18. With a forward yield of ~4.6%, the shares don’t look obviously cheap, but we feel that this is a fair price to pay given the long runway of rental growth ahead.
A post-result bounce in the Commonwealth Bank of Australia (ASX: CBA) share price helped lift the Australian share market on Wednesday.
The Suncorp Group Ltd (ASX: SUN) share price was trading 1.7% lower on Wednesday afternoon despite posting an excellent profit result. So what’s up with the Suncorp share price? Stock Doctor’s Daniel Ortisi explains…
The Commonwealth Bank of Australia (ASX: CBA) share price is in focus after the ASX’s largest bank share released its FY23 result.
Pro Medicus Ltd (ASX:PME) shares and Xero Limited (ASX:XRO) shares my two biggest ASX shareholdings. If you want to know why I own Pro Medicus or Xero shares, read this.
Reporting season might be a handy time to buy top ASX shares that look good value. I’m calling these two ASX shares opportunities.
Is JB Hi-Fi Limited (ASX: JBH) the ASX’s best business model? Drew thinks so. Or is Pinnacle Investment Management Ltd (ASX: PNI) a much better business?
The Commonwealth Bank of Australia (ASX: CBA) share price jumped after reporting results. But was it really a good result for CBA shareholders? Stock Doctor’s Daniel Ortisi takes a deep look.
The Nick Scali Limited (ASX:NCK) share price has gone up after revealing a strong FY23 report and generous dividend.
The team at Stock Doctor initiated coverage of ARF as a Star Income Stock in 2017 at a share price of $2.18. With a forward yield of ~4.6%, the shares don’t look obviously cheap, but we feel that this is a fair price to pay given the long runway of rental growth ahead.
A post-result bounce in the Commonwealth Bank of Australia (ASX: CBA) share price helped lift the Australian share market on Wednesday.
The Suncorp Group Ltd (ASX: SUN) share price was trading 1.7% lower on Wednesday afternoon despite posting an excellent profit result. So what’s up with the Suncorp share price? Stock Doctor’s Daniel Ortisi explains…
The Commonwealth Bank of Australia (ASX: CBA) share price is in focus after the ASX’s largest bank share released its FY23 result.
Pro Medicus Ltd (ASX:PME) shares and Xero Limited (ASX:XRO) shares my two biggest ASX shareholdings. If you want to know why I own Pro Medicus or Xero shares, read this.
Reporting season might be a handy time to buy top ASX shares that look good value. I’m calling these two ASX shares opportunities.
Want to level-up your analytical skills and investing insights but don’t know where to start? We can help. Join 40,000+ Australian investors on our mailing list today and we’ll send you our favourite podcasts, courses, resources, investment articles and podcasts every week. Delivered to your inbox every Sunday morning. Grab a coffee and let Owen and the team bring you the best investment insights every week.
The information on this website is general financial advice only. That means, the advice does not take into account your objectives, financial situation or needs. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. In addition, you should obtain and read the product disclosure statement (PDS) and Target Market Determination before making a decision to acquire any financial product. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. Please read our Terms & Conditions and Financial Services Guide before using this website.
“Rask Invest” is considered a financial product and has a Product Disclosure Statement (PDS) and Target Market Determination (TMD), issued by InvestSMART. These documents can be accessed on the Rask Invest website. Please seek professional advice before making any investment decision with respect to Rask Invest.
© Rask Australia 2024
